Skip to main content

Advertisement

SpringerLink
Log in

Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin

  • Clinical Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

Fourteen women with postmenopausal osteoporosis, all having at least one vertebral crush fracture, were randomly assigned to two treatment arms, each lasting 24 months. The coherence treatment group (7 patients) was treated in the following sequence: human growth hormone (hGH) 7 IU subcutaneously daily for 2 months, followed by 3 months of salmon calcitonin (CT), 100 MRC units every other day. After a 3 month rest period, this sequence was repeated twice. The contrast group (7 patients) was treated intermittently with salmon CT given in the same time periods and at the same dose as in the coherence treatment group. Bone mass was measured every 4 months by neutron activation analysis for total body calcium (TBCa) and by single photon absorptiometry for bone mineral content (BMC) of the distal radius. Although there were no significant differences between the two groups (two-way ANOVA), the rate of change in TBCa in the coherence treatment group was significantly different from zero (F=3.8,P<.05) and was +2.3%/year. The increase in bone mass appeared to be sustained throughout the 2 year study, in contrast with previous studies where a plateau effect was observed with calcitonin given alone or continuously with growth hormone. No significant change was found in bone histomorphometric values measured before and after treatment in 4 patients from each group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Riggs BL, Jowsey J, Goldsmith RS, Kelly PJ, Hoffman DL, Arnaud CD (1972) Short-and long-term effects of estrogen and synthetic anabolic hormones in postmenopausal osteoporosis. J Clin Invest 51:1659–1663

    Article  PubMed  CAS  Google Scholar 

  2. Aloia JF, Zanzi I, Vaswani A, Ellis K, Cohn SH (1982) Combination therapy for osteoporosis with estrogen, fluoride and calcium. J Am Geriatr Soc 30:13–17

    PubMed  CAS  Google Scholar 

  3. Aloia JF, Zanzi I, Vaswani A, Ellis K, Cohn SH (1977) Combination therapy for osteoporosis. Metabolism 26:787–792

    Article  PubMed  CAS  Google Scholar 

  4. Wallach S, Cohn SH, Atkins, HL, Ellis KJ, Kohberger R, Aloia JF, Zanzi I (1977) Effects of salmon calcitonin on skeletal mass in osteoporosis. Curr Therap Res 22:556–572

    Google Scholar 

  5. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM (1982) Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 306:446–450

    Article  PubMed  CAS  Google Scholar 

  6. Chesnut CH 3rd, Ivey JL, Gruber HE, Matthews M, Nelp WB, Sisom K, Baylink DJ (1983) Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism 32:571–580

    Article  PubMed  Google Scholar 

  7. Briancon D, Meunier PJ (1981) Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin N Am 12:629–648

    CAS  Google Scholar 

  8. Aloia JF, Vaswani A, Kapoor A, Yeh, JK, Cohn SH (1985) Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 34:124–129

    Article  PubMed  CAS  Google Scholar 

  9. Cohn SH, Ellis KJ, Wallach S, Zanzi I, Atkins HL, Aloia JF (1974) Absolute and relative deficit in total skeletal calcium and radial bone mineral in osteoporosis. J Nucl Med 15:428–435

    PubMed  CAS  Google Scholar 

  10. Meunier PJ, Sellami S, Briancon D Edouard C (1981) Histological heterogeneity of apparently idiopathic osteoporosis. In: DeLuca HF (ed) Osteoporosis. Recent advances in pathogenesis and treatment. University Park Press, Baltimore, pp 293–302

    Google Scholar 

  11. Parfitt AM (1980) Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Mineral Electrolyte Metab 4:273–287

    Google Scholar 

  12. Meunier PJ, Bianchi GS, Edouard C, Bernard JC, Courpron P, Vignon G (1972) Bony manifestation of thyrotoxicosis. Orthop Clin N Am 3:745–774

    Google Scholar 

  13. Frost HM (1981) Coherence treatment of osteoporoses Orthop Clin N Am 12:649–669

    CAS  Google Scholar 

  14. Aloia JF, Zanzi I, Ellis K, Jowsey J, Roginsky MS, Wallach S, Cohn SH (1976) Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 54:992–999

    Google Scholar 

  15. Haas HG, Dambacher MA, Goschke H, Guncaga J, Lauffenburger T (1976) Growth hormone in osteoporosis. Calcif Tissue Res 21 (suppl):467–468

    PubMed  Google Scholar 

  16. Harris WH, Heaney RP (1969) Effect of growth hormone on skeletal mass in adult dogs. Nature (London) 223:403–404

    Article  CAS  Google Scholar 

  17. Cohn SK, Sukla KK, Dombrowski CS, Fairchild RG (1972) Design and calibration of a “broad-beam”238Pu, Be neutron source for total body neutron activation analysis. J Nucl Med 13:487–489

    PubMed  CAS  Google Scholar 

  18. Cohn SH, Dombrowski CS, Pate RH, Robertson JS (1969) A whole body counter with an invariant response to radionuclide distribution and body size. Phys Med Biol 14:645–658

    Article  PubMed  CAS  Google Scholar 

  19. Cameron JR, Mazess RB, Soreson JA (1968) Precision and accuracy of bone mineral determination by direct photon absorptiometry. Invest Radiol 3:141–150

    Article  PubMed  CAS  Google Scholar 

  20. Eisman JA, Hamstra AJ, Kream BE, DeLuca HF (1976) A sensitive precise and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma. Arch Biochem Biophys 176:235–243

    Article  PubMed  CAS  Google Scholar 

  21. Prockop DJ, Udenfriend S (1970) A specific method for the analysis of hydroxyproline in urine. Anal Biochem 1:228–239

    Article  Google Scholar 

  22. Meunier PJ, Bressot C (1982) Endocrine influence on bone cells and bone remodelling evaluated by clinical histomorphometry. In: Parsons JA (ed) Endocrinology of calcium metabolism. Raven Press, New York, pp 445–465

    Google Scholar 

  23. Chavassieux PM, Arlot ME, Meunier PJ (1985) Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37:345–350

    PubMed  CAS  Google Scholar 

  24. Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonnelli S, Ferrara R, Zacchei F (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464

    Google Scholar 

  25. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303

    Article  PubMed  CAS  Google Scholar 

  26. Anderson C, Cape RD, Crilly RG, Hodsman AB, Wolfe BM (1984) Preliminary observations of a form of coherence therapy for osteoporosis. Calcif Tissue Int 36:341–343

    Article  PubMed  CAS  Google Scholar 

  27. Rasmussen H (1980) Theoretical considerations in the treatment of osteoporosis. In: DeLuca HF, Frost HM, Jee WSS, Johnston CC, Parfitt AM (eds) Osteoporosis: recent advances in pathogenesis and treatment. University Park Press, Baltimore, pp 383–392

    Google Scholar 

  28. Neer R, Slovik D, Adams J, Holick M, Potts JT (1980) Interactions of synthetic human parathyroid hormone fragment I-34 with other agents in osteoporotic patients. In: DeLuca HF, Frost HM, Jee WSS, Johnston CC, Parfitt AM (eds) Osteoporosis: recent advances in pathogenesis and treatment. University Park Press, Baltimore, pp 467–470

    Google Scholar 

  29. Chipman JJ, Zerwekh J, Nicar M, Marks J, Pak CYC (1980) Effect of growth hormone administration: reciprocal changes in serum 1,25-dihydroxyvitamin D and intestinal calcium absorption. J Clin Endocrinol Metab 51:321–324

    Article  PubMed  CAS  Google Scholar 

  30. Brown P, Gajdusek DC, Gibbs, CJ Jr, Asher DM (1985) Potential epidemic of Creutzfeld-Jakob disease from human growth hormone therapy. N Engl J Med 313:728–731

    Article  PubMed  CAS  Google Scholar 

  31. Gibbs CJ Jr, Joy A, Heffner R, Franko M, Miyazarki M, Asher D, Parisi J, Brown PW, Gajdusek DC (1985) Clinical and pathological features and laboratory confirmation of Creutzfeld-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 313:734–738

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Winthrop-University Hospital, 259 First Street, 11501, Mineola, NY, New York

    John F. Aloia M.D., Ashok Vaswani & James K. Yeh

  2. Brookhaven National Laboratory, Upton, New York

    Ashok Vaswani & Stanton H. Cohn

  3. Health Sciences Center, State University of New York at Stony, Stony Brook, USA

    John F. Aloia M.D., Ashok Vaswani, James K. Yeh & Stanton H. Cohn

  4. the INSERM Unit 234, Paculty Alexis Carrel, Lyon, France

    Pierre J. Meunier, Claude M. Edouard & Monique E. Arlot

Authors
  1. John F. Aloia M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashok Vaswani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre J. Meunier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claude M. Edouard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Monique E. Arlot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James K. Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stanton H. Cohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aloia, J.F., Vaswani, A., Meunier, P.J. et al. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin. Calcif Tissue Int 40, 253–259 (1987). https://doi.org/10.1007/BF02555257

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02555257

Key words

Search

Navigation